STRAUMANN HLDG NA SF 0,01
STRAUMANN HLDG NA SF 0,01/ CH1175448666 /
QS51
- -
|
Chg.
-
|
Volume |
Bid- |
Ask- |
Market Capitalization |
Dividend Y. |
P/E Ratio |
-EUR
|
-
|
- Turnover: - |
-Bid Size: - |
-Ask Size: - |
18.05 bill.EUR |
- |
- |
Business description
Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and biomaterials for use in tooth replacement and restoration solutions or to prevent tooth loss.
Management board & Supervisory board
CEO |
Guillaume Daniellot |
Management board |
Dr. Peter Hackel, Camila Finzi, Wolfgang Becker, Jason Forbes , Holger Haderer, Patrick Loh , Alastair Robertson, Sébastien Roche, Aurelio Sahagun, Rahma Samow, Matthias Schupp, Dr Christian Ullrich |
Supervisory board |
Petra Rumpf, Dr. Beat Lüthi, Dr. Thomas Straumann, Marco Gadola, Regula Wallimann, Xiaoqun Clever-Steg, Stefan Meister, Olivier Filliol, Regula Wallimann |
Company data
Name: |
Straumann Holding AG |
Address: |
Peter Merian-Weg 12,CH-4052 Basel |
Phone: |
+41-61-965-1111 |
Fax: |
+41-61-965-1101 |
E-mail: |
info@straumann.com
|
Internet: |
www.straumann.com |
Industry: |
Healthcare |
Sector: |
Medical Products |
Sub sector: |
Advanced Medical Devices |
End of financial year: |
12-31 |
Free Float: |
57.90% |
IPO date: |
1998-01-01 |
Company calendar
CW 33 | 2024-08-14
Interim Report 2nd Quarter/6 Months
|
CW 44 | 2024-10-29
Interim Report 3rd Quarter/9 Months
|